Senores Pharmaceuticals Announces ₹43 Crore Manufacturing Capacity Expansion in India and USA

Senores Pharmaceuticals Limited has announced a ₹43 crore investment to expand pharmaceutical manufacturing capacity across three subsidiaries in India and the United States, targeting completion by March 2027.

The expansion includes ₹18 crore for Havix Group Inc., USA, increasing annual production capacity from 1.2 billion to 2 billion units, adding 800 million units.

In India, subsidiary Apnar Pharma Private Limited will invest ₹20 crore to increase annual manufacturing capacity from 500 million to 1.2 billion units, representing an additional 700 million units.

Additionally, Ratnatris Pharmaceuticals Private Limited will invest ₹5 crore to establish a new prefilled syringe manufacturing line with an annual capacity of 2.7 million units.

Together, these projects will add approximately 1.503 billion units annually. Funded through internal accruals and IPO proceeds, the expansions aim to meet growing pharmaceutical demand, enhance production capabilities and strengthen Senores Pharmaceuticals' manufacturing presence across domestic and international markets.